All Updates

All Updates

icon
Filter
Product updates
VeriSIM Life launches AtlasGEN novel drug discovery platform
AI Drug Discovery
Apr 3, 2024
This week:
Partnerships
T-Mobile partners with OpenAI to develop AI-powered customer service platform
Generative AI Applications
Today
Partnerships
Runway partners with Lionsgate to develop AI video tools using studio's movie catalog
Generative AI Applications
Yesterday
Funding
QMill raises EUR 4 million in seed funding to provide quantum computing industrial applications
Quantum Computing
Yesterday
Product updates
QuiX Quantum launches 'Bia' quantum cloud computing service for quantum solutions
Quantum Computing
Yesterday
Partnerships
Oxford Ionics and Infineon Technologies partner to build portable quantum computer for Cyberagentur
Quantum Computing
Yesterday
Partnerships
Product updates
Tencent Ai Lab launches EzAudio AI for text-to-audio generation with Johns Hopkins University
Foundation Models
Yesterday
Funding
TON secures USD 30 million in investment from Bitget and Foresight Ventures
Web3 Ecosystem
Yesterday
Funding
Hemi Labs raises USD 15 million in funding to launch blockchain network
Web3 Ecosystem
Yesterday
Product updates
Fivetran launches Hybrid Deployment for data pipeline management
Machine Learning Infrastructure
Yesterday
Product updates
Fivetran launches Hybrid Deployment for data pipeline management
Data Infrastructure & Analytics
Yesterday
AI Drug Discovery

AI Drug Discovery

Apr 3, 2024

VeriSIM Life launches AtlasGEN novel drug discovery platform

Product updates

  • VeriSIM Life has announced the launch of AtlasGEN Novel Drug Designer, a platform that focuses on combining generative chemical discovery and biological validation to increase efficiency in drug candidate selection. The platform is part of the BIOiSIM platform that uses a unique Translational Index, akin to a credit score, to give insights into the AI analysis and the potential effectiveness and safety of created compounds.

  • The key features of AtlasGEN include the ability to not only design drug compounds based on chemical aspects but also factor in biological translation, ensuring the drugs' functionality and safety in the human body. This approach considerably lowers the need for experimental validation, reducing development costs.

  • VeriSIM Life claims that AtlasGEN can accelerate new drug development, decreasing the cost while increasing the likelihood of drugs making it to clinical trials. By integrating generative AI with bio knowledge systems, it offers a robust solution for computational drug design, instrumental in treating millions of patients with diseases currently lacking effective treatments.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.